10 Best Healthcare Software for November 2025
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The current market landscape is marked by sector rotation and a renewed focus on quality fundamentals, with technology and healthcare leading innovation and defensive growth. ValueSense’s selection methodology combines intrinsic value analysis, quality ratings, and proprietary screening tools to identify stocks with strong financial metrics, robust free cash flow, and sector leadership. Each pick is evaluated for growth potential, risk profile, and alignment with long-term value investing principles[1][2].
Featured Stock Analysis
Amazon.com, Inc. (AMZN)
| Metric | Value |
|---|---|
| Market Cap | $2,606.8B |
| Quality Rating | 6.1 |
| Intrinsic Value | $90.7 |
| 1Y Return | 31.0% |
| Revenue | $691.3B |
| Free Cash Flow | $10.6B |
| Revenue Growth | 11.5% |
| FCF margin | 1.5% |
| Gross margin | 49.4% |
| ROIC | 14.4% |
| Total Debt to Equity | 36.6% |
Investment Thesis
Amazon remains a dominant force in global e-commerce and cloud computing, with a market cap of $2.6 trillion. Despite its scale, ValueSense’s intrinsic value estimate $90.7 suggests caution, as the current price far exceeds this baseline. Amazon’s 1-year return of 31% reflects resilience in retail and AWS, supported by $691.3B in revenue and a 49.4% gross margin. The company’s ROIC of 14.4% and manageable debt-to-equity ratio 36.6% indicate solid capital efficiency.
Key Catalysts
- Continued expansion of AWS and cloud services
- Growth in advertising and subscription revenue streams
- Strategic investments in logistics and AI-driven fulfillment
Risk Factors
- High valuation relative to intrinsic value
- Margin pressure from retail competition
- Regulatory scrutiny in US and EU markets
ServiceNow, Inc. (NOW)
| Metric | Value |
|---|---|
| Market Cap | $191.2B |
| Quality Rating | 7.1 |
| Intrinsic Value | $306.6 |
| 1Y Return | -1.5% |
| Revenue | $12.7B |
| Free Cash Flow | $3,958.0M |
| Revenue Growth | 21.1% |
| FCF margin | 31.2% |
| Gross margin | 78.1% |
| ROIC | 20.2% |
| Total Debt to Equity | 21.3% |
Investment Thesis
ServiceNow is a leader in enterprise workflow automation, with a $191.2B market cap and a robust quality rating of 7.1. The company’s intrinsic value $306.6 is below its current market price, but its fundamentals are compelling: 21.1% revenue growth, 31.2% FCF margin, and a stellar 78.1% gross margin. ServiceNow’s ROIC of 20.2% and low debt-to-equity 21.3% highlight operational excellence.
Key Catalysts
- Expansion into AI-driven automation and digital transformation
- Strong customer retention and upsell opportunities
- Strategic partnerships with cloud providers
Risk Factors
- Valuation premium versus intrinsic value
- Competitive pressure from legacy and emerging SaaS providers
- Sensitivity to enterprise IT spending cycles
IDEXX Laboratories, Inc. (IDXX)
| Metric | Value |
|---|---|
| Market Cap | $50.6B |
| Quality Rating | 7.5 |
| Intrinsic Value | $210.3 |
| 1Y Return | 54.7% |
| Revenue | $4,037.7M |
| Free Cash Flow | $774.3M |
| Revenue Growth | 6.7% |
| FCF margin | 19.2% |
| Gross margin | 61.5% |
| ROIC | 44.5% |
| Total Debt to Equity | 84.8% |
Investment Thesis
IDEXX Laboratories is a global leader in veterinary diagnostics, boasting a $50.6B market cap and a high quality rating of 7.5. Its intrinsic value $210.3 is well below current market levels, but the company’s 54.7% 1-year return and 6.7% revenue growth underscore strong sector momentum. With a 61.5% gross margin and an exceptional ROIC of 44.5%, IDEXX demonstrates industry-leading profitability.
Key Catalysts
- Expansion of diagnostic product portfolio
- Growth in companion animal healthcare spending
- International market penetration
Risk Factors
- Premium valuation
- Exposure to cyclical pet care trends
- High debt-to-equity ratio 84.8%
Roper Technologies, Inc. (ROP)
| Metric | Value |
|---|---|
| Market Cap | $48.0B |
| Quality Rating | 6.1 |
| Intrinsic Value | $509.7 |
| 1Y Return | -16.9% |
| Revenue | $7,721.0M |
| Free Cash Flow | $2,460.1M |
| Revenue Growth | 14.0% |
| FCF margin | 31.9% |
| Gross margin | 69.0% |
| ROIC | 5.5% |
| Total Debt to Equity | 45.8% |
Investment Thesis
Roper Technologies, with a $48.0B market cap and a quality rating of 6.1, specializes in diversified technology solutions. Despite a -16.9% 1-year return, the company’s 14% revenue growth and 31.9% FCF margin highlight underlying strength. Roper’s intrinsic value $509.7 suggests undervaluation potential, supported by a 69% gross margin.
Key Catalysts
- Portfolio realignment toward high-margin software
- Strategic acquisitions
- Operational efficiency improvements
Risk Factors
- Recent share price underperformance
- Integration risks from acquisitions
- Moderate ROIC 5.5% compared to peers
Veeva Systems Inc. (VEEV)
| Metric | Value |
|---|---|
| Market Cap | $47.5B |
| Quality Rating | 7.7 |
| Intrinsic Value | $148.4 |
| 1Y Return | 39.4% |
| Revenue | $2,968.2M |
| Free Cash Flow | $1,332.3M |
| Revenue Growth | 15.3% |
| FCF margin | 44.9% |
| Gross margin | 75.6% |
| ROIC | 51.8% |
| Total Debt to Equity | 1.3% |
Investment Thesis
Veeva Systems is a cloud leader in life sciences, with a $47.5B market cap and the highest quality rating in this list 7.7. Its intrinsic value $148.4 is below current price, but Veeva’s 39.4% 1-year return, 15.3% revenue growth, and 44.9% FCF margin are notable. The company’s 75.6% gross margin and 51.8% ROIC reflect best-in-class profitability and capital allocation.
Key Catalysts
- Expansion of clinical and regulatory cloud platforms
- Deepening relationships with pharma and biotech clients
- Minimal debt (1.3% debt-to-equity)
Risk Factors
- Premium valuation
- Dependence on life sciences sector growth
- Potential for competitive disruption
IQVIA Holdings Inc. (IQV)
| Metric | Value |
|---|---|
| Market Cap | $36.8B |
| Quality Rating | 6.6 |
| Intrinsic Value | $330.0 |
| 1Y Return | 5.2% |
| Revenue | $15.9B |
| Free Cash Flow | $2,640.0M |
| Revenue Growth | 3.5% |
| FCF margin | 16.6% |
| Gross margin | 33.8% |
| ROIC | 8.9% |
| Total Debt to Equity | 241.6% |
Investment Thesis
IQVIA is a global leader in clinical research and data analytics, with a $36.8B market cap and a quality rating of 6.6. Its intrinsic value $330.0 is below current price, but IQVIA’s 5.2% 1-year return and 3.5% revenue growth reflect steady performance. The company’s 16.6% FCF margin and 8.9% ROIC are solid, though its debt-to-equity ratio 241.6% is a concern.
Key Catalysts
- Growth in real-world evidence and data services
- Expansion of clinical trial outsourcing
- Strategic technology investments
Risk Factors
- High leverage
- Regulatory and compliance risks
- Slower revenue growth
Fresenius Medical Care AG & Co. KGaA (FMS)
| Metric | Value |
|---|---|
| Market Cap | $15.8B |
| Quality Rating | 5.7 |
| Intrinsic Value | $71.2 |
| 1Y Return | 37.4% |
| Revenue | €19.5B |
| Free Cash Flow | €2,326.4M |
| Revenue Growth | 0.5% |
| FCF margin | 11.9% |
| Gross margin | 24.7% |
| ROIC | 4.3% |
| Total Debt to Equity | 77.0% |
Investment Thesis
Fresenius Medical Care is a global provider of dialysis products and services, with a $15.8B market cap and a quality rating of 5.7. Its intrinsic value €71.2 is below current price, and the company posted a 37.4% 1-year return despite modest revenue growth 0.5%. FMS’s 11.9% FCF margin and 24.7% gross margin are stable, though ROIC 4.3% and debt-to-equity 77% warrant caution.
Key Catalysts
- Expansion of global dialysis network
- Innovation in renal care products
- Cost optimization initiatives
Risk Factors
- Low revenue growth
- High debt levels
- Regulatory risks in healthcare markets
ICON Public Limited Company (ICLR)
| Metric | Value |
|---|---|
| Market Cap | $13.3B |
| Quality Rating | 6.0 |
| Intrinsic Value | $304.2 |
| 1Y Return | -22.6% |
| Revenue | $8,102.6M |
| Free Cash Flow | $995.8M |
| Revenue Growth | (2.5%) |
| FCF margin | 12.3% |
| Gross margin | 26.9% |
| ROIC | 8.6% |
| Total Debt to Equity | 7.0% |
Investment Thesis
ICON is a leading clinical research organization, with a $13.3B market cap and a quality rating of 6.0. Its intrinsic value $304.2 is below current price, and the company’s -22.6% 1-year return and 2.5% revenue growth reflect sector headwinds. However, ICON’s 12.3% FCF margin and low debt-to-equity 7% provide financial flexibility.
Key Catalysts
- Growth in outsourced clinical trials
- Expansion into new therapeutic areas
- Strategic partnerships
Risk Factors
- Recent revenue contraction
- Competitive pressures
- Market volatility in biotech
Doximity, Inc. (DOCS)
| Metric | Value |
|---|---|
| Market Cap | $12.4B |
| Quality Rating | 8.4 |
| Intrinsic Value | $28.0 |
| 1Y Return | 58.2% |
| Revenue | $589.6M |
| Free Cash Flow | $292.4M |
| Revenue Growth | 19.4% |
| FCF margin | 49.6% |
| Gross margin | 90.1% |
| ROIC | 78.4% |
| Total Debt to Equity | 1.4% |
Investment Thesis
Doximity is a digital platform for medical professionals, with a $12.4B market cap and the highest quality rating 8.4 in this collection. Its intrinsic value $28.0 is below current price, but Doximity’s 58.2% 1-year return, 19.4% revenue growth, and 49.6% FCF margin are exceptional. The company’s 90.1% gross margin and 78.4% ROIC highlight outstanding profitability and capital efficiency.
Key Catalysts
- Expansion of telehealth and networking services
- Growth in digital advertising and recruitment
- Minimal debt (1.4% debt-to-equity)
Risk Factors
- High valuation
- Dependence on healthcare sector trends
- Platform competition
Crane Company (CR)
| Metric | Value |
|---|---|
| Market Cap | $10.9B |
| Quality Rating | 6.1 |
| Intrinsic Value | $104.0 |
| 1Y Return | 21.1% |
| Revenue | $2,111.5M |
| Free Cash Flow | $59.2M |
| Revenue Growth | (7.3%) |
| FCF margin | 2.8% |
| Gross margin | 43.4% |
| ROIC | 19.0% |
| Total Debt to Equity | 0.0% |
Investment Thesis
Crane Company operates in industrial manufacturing, with a $10.9B market cap and a quality rating of 6.1. Its intrinsic value $104.0 is below current price, and the company posted a 21.1% 1-year return despite 7.3% revenue contraction. Crane’s 2.8% FCF margin and 43.4% gross margin are modest, but its 19% ROIC and zero debt-to-equity indicate strong financial discipline.
Key Catalysts
- Portfolio optimization and cost management
- Expansion into specialty industrial segments
- Strong capital allocation
Risk Factors
- Declining revenue
- Cyclical exposure to industrial demand
- Limited growth drivers
Portfolio Diversification Insights
This watchlist spans technology, healthcare, and industrial sectors, balancing growth and defensive characteristics. Technology stocks (AMZN, NOW, VEEV, DOCS) offer innovation and scalability, while healthcare picks (IDXX, IQV, FMS, ICLR) provide stability and exposure to demographic trends. Crane Company adds industrial diversification, reducing sector concentration risk. The mix of high ROIC, varied debt profiles, and differentiated business models supports portfolio resilience.
Market Timing & Entry Strategies
ValueSense’s intrinsic value analysis highlights potential entry points when market prices approach or fall below estimated fair value. Investors may consider dollar-cost averaging into positions with strong quality ratings and positive free cash flow trends. Monitoring sector rotation and macroeconomic signals can further refine timing, while diversification across sectors helps mitigate volatility[1][2].
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- How VKTX (Viking Therapeutics) Makes Money in 2025: A Deep-Dive With Income Statement
- How NET (Cloudflare) Makes Money in 2025: A Deep-Dive With Income Statement
- How MASS (908 Devices) Makes Money in 2025: A Deep-Dive With Income Statement
- How CRVO (CervoMed) Makes Money in 2025: A Deep-Dive With Income Statement
- How GILD (Gilead Sciences) Makes Money in 2025: A Deep-Dive With Income Statement
FAQ Section
Q1: How were these stocks selected?
Stocks were chosen using ValueSense’s proprietary screening tools, focusing on intrinsic value, quality ratings, and fundamental financial metrics such as revenue growth, free cash flow, and sector leadership[1][2].
Q2: What's the best stock from this list?
Each stock offers unique strengths; Doximity (DOCS) and Veeva Systems (VEEV) stand out for their high quality ratings and profitability, while Amazon (AMZN) and ServiceNow (NOW) provide scale and innovation. The “best” depends on individual investment goals and risk tolerance.
Q3: Should I buy all these stocks or diversify?
Diversification across sectors (technology, healthcare, industrials) can reduce risk and improve portfolio stability. ValueSense’s watchlist is designed to provide balanced exposure rather than concentrated bets.
Q4: What are the biggest risks with these picks?
Key risks include premium valuations, sector-specific headwinds, regulatory changes, and company-specific financial concerns such as high debt or slowing growth. Each analysis section details relevant risk factors.
Q5: When is the best time to invest in these stocks?
Entry timing can be optimized by monitoring intrinsic value estimates, sector trends, and macroeconomic signals. ValueSense’s tools help identify when stocks are undervalued relative to their fundamentals, supporting informed decision-making[1][2].